Skip to main content
. 2017 Feb 21;8(14):23360–23375. doi: 10.18632/oncotarget.15579

Figure 1. Comparison of miR-155 expressions in MPs, plasma and T lymphocytes from peripheral blood of aGVHD (n = 28) and non-aGVHD (n = 30) patients.

Figure 1

Data represent the mean ± SD. (A) miR-155 expressions in MPs of aGVHD and non-aGVHD patients. ***P < 0.001, comparison between aGVHD and non-aGVHD at +7d, +14d, +21d, +28d. ###P < 0.001, miR-155 levels in MPs of aGVHD patients at +7d, +14d, +21d, +28d and aGVHD point were compared with pre-HSCT level. (B) miR-155 expressions in plasma of aGVHD and non-aGVHD patients. *P < 0.01, comparison between aGVHD and non-aGVHD at +14d. ***P < 0.001, comparison between aGVHD and non-aGVHD at +7d, +21d, +28d. ###P < 0.001, miR-155 levels in plasma at +7d, +28d and aGVHD point were compared with pre-HSCT level. (C) miR-155 expressions in MPs and plasma from aGVHD patients. ***P < 0.001, miR-155 expressions in MPs pre-HSCT, at +7d, +14d, +21d, +28d and aGVHD point were compared with plasma. (D) miR-155 expressions in T lymphocytes of aGVHD and non-aGVHD patients. ###P < 0.001, miR-155 level in T lymphocytes at aGVHD point was compared with pre-HSCT level.